AtriCure Q2 2022 revenue $84.5M (+18.4%); net loss $0.32/share; FY guidance unchanged

AtriCure, Inc.

2022-Q2 EPS reported -$0.66 revenue$159,105,000

Revenue $84.5M (+18.4% YoY; +19.8% constant currency); U.S. $71.3M (+18.6%), international $13.3M (+17.3%).
Gross margin 75.1% vs 75.8% prior; operating loss $13.7M vs $15.1M prior.
Net loss per share $0.32 (adjusted $0.32) vs $0.36 GAAP and $0.30 adjusted prior year.
Adjusted EBITDA loss $3.2M vs $2.7M prior; FY 2022 revenue guide $323M-$333M (18-21% growth).
Growth driven by cryoSPHERE, AtriClip, ENCOMPASS, and EPi-Sense products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.